How To Progress Safe And Effective Cell Therapies For Clinical Use

Sistemic to present miRNA-led cell characterisation at Stem Cell Europe

Sistemic believe cell characterisation is an essential element in progressing safe and effective cell therapies for mainstream clinical use. They offer unique miRNA analytical services that provide reliable and cost-effective, characterisation and QC tools that are applicable to all cell systems. Toward this end, Dr Vincent O'Brien (Chief Scientific Officer) and Dr Verna McErlane (Director of Commercial Operations, International) will present data supporting the utility of miRNA in the provision of superior cell characterisation and QC methods at the forthcoming Stem Cells Europe conference (20-21 July 2011, Edinburgh).

Dr. Vincent O'Brien will present a poster entitled; ‘A novel microRNA-based stem cell characterisation and monitoring tool',and Verna McErlane will join: Marilyn Robertson, SSCN; Aidan Courtney, Roslin Cells; Dr. David Hay, Fibromed; and, Michael Leek, Immunosolv, at the Scottish Stem Cell Network (SSCN) Panel showcase, "Progress to Therapy and Market" on Wednesday 20 July at 5pm.

Sistemic Ltd are a global company offering unique miRNA-based products and services such as SistemQC, designed for the sophisticated molecular characterisation of cells, which combines robust miRNA profiling, statistical analysis and contextual analysis. Further information on all Sistemic's proprietary services, including; SistemRNA, SistemQC, SistemTOX and SistemKB, can be found at: www.sistemic.co.uk

About Sistemic Ltd.
Sistemic is focused on providing innovative microRNA-based problem-solving services to areas of unmet need within Pharmaceutical and Biotechnology R&D and manufacturing. MicroRNAs are perceived as the master controllers of the cell and mediate a wide range of cell functions and responses. Sistemic has developed miRNA profiling technology where a cell's whole microRNA response to a stimulus (chemical or biological) can be analysed, interpreted, compared to the Sistemic Knowledgebase of miRNA response and then provided to the client as useful and functional data. In this way a cell can be subjected to a single assay and its full biological response can be obtained, to give the client a more complete understanding of their system.

VincentO'Brien is a co-founder of Sistemic and was formerly a Senior Fellow at Imperial College London where he continued research into acquired drug resistance, epigenetic therapies and biomarker discovery he started at the University of Glasgow (Centre for Oncology and Applied Pharmacology). He has published and lectured extensively and won both SMART Feasibility and R&D grant awards from the Scottish Government.

Verna McErlane has earned an international reputation in the business end of bio-analytics. Having gained her PhD in the area of pre-clinical cancer drug development she spent time working at the Gray Cancer Institute in London, before moving to the University of Dundee, Scotland to pursue evaluation of prodrug anticancer strategies. Dr Mc Erlane has worked with many international companies including: SPEAR Therapeutics Ltd, Genzyme and Axis-Shield on international market development and new business initiatives.

SOURCE: Sistemic Ltd.